Canaccord cuts Boston Scientific stock price target on guidance reduction By Investing.com

Canaccord cut Boston Scientific’s price target to $71 from $109 while keeping a Buy rating, reflecting more cautious expectations after the company lowered 2026 guidance. Q1 revenue was $5.2 billion, up 11.6% reported and 9.4% organic, with adjusted EPS of $0.80, but weakness in Urology, Watchman, and Electrophysiology is pressuring the outlook. Boston Scientific also committed to a $2 billion share buyback in Q2, partially offsetting the softer guidance tone.

Analysis

This is less a one-quarter miss and more a credibility reset on the long-duration growth story. When a premium medtech name cuts outer-year expectations while still leaning on buybacks, the market usually starts valuing the stock as a nearer-term earnings compounder rather than a durable multiple-expansion compounder; that often compresses the terminal multiple even if near-term fundamentals remain solid. The fact that weakness is concentrated in a few franchises matters because it raises the probability of channel caution, salesforce distraction, and slower procedure conversion beyond the named categories.

The second-order issue is that peers may briefly benefit from repatriated capital and delayed procedure decisions. If physicians are reallocating cases or waiting for evidence/ramp clarity, that can advantage more diversified cardiovascular or diabetes-device platforms with cleaner launch cadence and less dependence on a few high-expectation franchises. Suppliers tied to BSX-specific component demand should also see softer pull-through, but the bigger effect is likely on investor positioning: growth funds may de-risk medical devices broadly until they can distinguish company-specific execution from a sector-wide elective-procedure slowdown.

The buyback is a useful floor, not a thesis. At this market cap, $2B is meaningful but not transformative, and in a de-rating event it may simply slow downside rather than restore confidence; the key catalyst is whether management can reframe 2027 growth with evidence of stabilization in the affected franchises. If that stabilization shows up over the next 1-2 quarters, the stock can rerate quickly because expectations have already been cut materially; if not, the name risks becoming a value trap disguised as a growth story.

Consensus appears to be underestimating how much guidance cuts matter when the business already trades as a quality compounder. The move may not be done if estimate revisions continue, but near-term downside is likely increasingly path-dependent on one or two franchise datapoints rather than the core portfolio. That creates a tradable window for relative-value investors: own quality peers with cleaner guidance and fade BSX on strength until revision risk is fully washed out.

Key Decisions for Investors

• Short BSX vs. long a diversified medtech peer basket for 4-8 weeks; the trade is a revision-risk pair trade, not a fundamental short. Risk/reward favors continuation of multiple compression if estimates keep drifting, with a stop on evidence of franchise stabilization.
• Sell cash-secured puts or structure a bullish put spread in BSX 1-2 quarters out, targeting the post-cut valuation reset. This expresses a view that the buyback and existing quality franchise should limit tail downside, while avoiding outright long exposure to further guidance risk.
• Rotate toward cleaner-growth device names on any BSX relief rally over the next month; the relative setup is better in names with less dependence on one or two soft franchises and more visible launch pipelines. Use BSX as the funding leg.
• For long-only portfolios, keep BSX on a watchlist rather than adding aggressively until the next two quarterly checks confirm stabilization in the weaker franchises. Entry should wait for revised guidance to be explicitly de-risked, not just repeated.